These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 34743319)
41. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725 [TBL] [Abstract][Full Text] [Related]
42. BDNF val66met polymorphism and depressive disorders in patients with acute coronary syndrome. Kang HJ; Bae KY; Kim SW; Shin IS; Hong YJ; Ahn Y; Jeong MH; Yoon JS; Kim JM J Affect Disord; 2016 Apr; 194():1-8. PubMed ID: 26795846 [TBL] [Abstract][Full Text] [Related]
43. Escitalopram in the treatment of anxiety symptoms associated with depression. Bandelow B; Andersen HF; Dolberg OT Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393 [TBL] [Abstract][Full Text] [Related]
44. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Bech P; Tanghøj P; Cialdella P; Andersen HF; Pedersen AG Int J Neuropsychopharmacol; 2004 Sep; 7(3):283-90. PubMed ID: 15320956 [TBL] [Abstract][Full Text] [Related]
45. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: Findings from the EsDEPACS study. Kim JW; Kang HJ; Bae KY; Kim SW; Shin IS; Yoon JS; Hong YJ; Ahn Y; Jeong MH; Kim JM Int J Psychiatry Med; 2019 Jan; 54(1):39-52. PubMed ID: 30079814 [TBL] [Abstract][Full Text] [Related]
46. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Griffiths RR; Johnson MW; Carducci MA; Umbricht A; Richards WA; Richards BD; Cosimano MP; Klinedinst MA J Psychopharmacol; 2016 Dec; 30(12):1181-1197. PubMed ID: 27909165 [TBL] [Abstract][Full Text] [Related]
47. A randomized, double-blind, placebo-controlled study of escitalopram in patients with social anxiety disorder in Japan. Asakura S; Hayano T; Hagino A; Koyama T Curr Med Res Opin; 2016; 32(4):749-57. PubMed ID: 26808688 [TBL] [Abstract][Full Text] [Related]
48. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667 [TBL] [Abstract][Full Text] [Related]
53. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Colonna L; Andersen HF; Reines EH Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906 [TBL] [Abstract][Full Text] [Related]
54. Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. Kim JM; Stewart R; Lee YS; Lee HJ; Kim MC; Kim JW; Kang HJ; Bae KY; Kim SW; Shin IS; Hong YJ; Kim JH; Ahn Y; Jeong MH; Yoon JS JAMA; 2018 Jul; 320(4):350-358. PubMed ID: 30043065 [TBL] [Abstract][Full Text] [Related]
55. Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study. Marschall J; Fejer G; Lempe P; Prochazkova L; Kuchar M; Hajkova K; van Elk M J Psychopharmacol; 2022 Jan; 36(1):97-113. PubMed ID: 34915762 [TBL] [Abstract][Full Text] [Related]
56. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. Gorman JM; Korotzer A; Su G CNS Spectr; 2002 Apr; 7(4 Suppl 1):40-4. PubMed ID: 15131492 [TBL] [Abstract][Full Text] [Related]
57. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Quednow BB; Kometer M; Geyer MA; Vollenweider FX Neuropsychopharmacology; 2012 Feb; 37(3):630-40. PubMed ID: 21956447 [TBL] [Abstract][Full Text] [Related]
58. Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity. Copa D; Erritzoe D; Giribaldi B; Nutt D; Carhart-Harris R; Tagliazucchi E J Affect Disord; 2024 May; 353():60-69. PubMed ID: 38423367 [TBL] [Abstract][Full Text] [Related]
59. The therapeutic potential of psilocybin: a systematic review. van Amsterdam J; van den Brink W Expert Opin Drug Saf; 2022 Jun; 21(6):833-840. PubMed ID: 35225143 [TBL] [Abstract][Full Text] [Related]
60. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Montgomery SA; Möller HJ Int Clin Psychopharmacol; 2009 May; 24(3):111-8. PubMed ID: 19357527 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]